Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Kaira K, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19. Cancer Chemother Pharmacol. 2017. PMID: 27995307 Clinical Trial.
Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Imai H, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2017 Mar;79(3):497-505. doi: 10.1007/s00280-016-3232-2. Epub 2017 Feb 6. Cancer Chemother Pharmacol. 2017. PMID: 28168310 Free PMC article.
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
Imai H, Sugiyama T, Tamura T, Minemura H, Kaira K, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2017 Sep;80(3):615-622. doi: 10.1007/s00280-017-3403-9. Epub 2017 Jul 31. Cancer Chemother Pharmacol. 2017. PMID: 28761968 Free PMC article.
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: minato k. Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8. Cancer Chemother Pharmacol. 2018. PMID: 29737372
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
Imai H, Yamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: minato k. Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14. Chemotherapy. 2018. PMID: 30107372
597 results